Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation

Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation. Pilot Study

Male Accessory Glands Inflammations (MAGI) include inflammatory diseases involving seminal vescicles and the prostate. Patients suffering from them present an impaired fertility because of seminal duct obstruction and alterations of the rheologic and functional parameters of semen, induced by direct microbiological action as well as inflammatory and oxidative damage. Inflammation in seminal plasma can be detected and measured by dosing of inflammatory molecules such as SuPAR and ST2. Treatment of MAGIs include specific antibiotic therapy in addition to use of anti-inflammatory nutraceutics. Deprox HP is a nutraceutic containing GraminexTM, a compound made of pollen extracts of rye, mais and timothy. To investigate its efficacy, we evalued seminal parameters, inflammatory and oxidative molecules in seminal plasma and clinical and ultrasonographic features of male accessory glands before and after 3 months of treatment in 20 patients taking Deprox HP and 20 patients undergoing treatment with palmitoilethanolammide, bromelin and horse chestnut extract.

Inclusion Criteria:

• Male patients with a diagnosis of MAGI based on clinical and/or ultrasonographic criteria.

Exclusion Criteria:

• History of cryptorchidism, orchitis, testicular torsion or trauma,
• Hypogonadism,
• Occupational chemical exposure,
• Y chromosome microdeletions, karyotype abnormalities and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutations,
• ultrasound testicular volume <12 mL,
• FSH >8 mUI/L,
• fever or drug use within 3 months prior to the enrollment in this study
• azoospermia.